Nanotechnology for Age-Related Macular Degeneration

Yang, Bo; Li, Ge; Liu, Jiaxin; Li, Xiangyu; Zhang, Shixin; Sun, Fengying; Liu, Wenhua

doi:10.3390/pharmaceutics13122035

Cited by 11 publications

(6 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a potential CRISPR/Cas delivery method, HA-based hydrogels have also been examined in other investigations. One experiment, for instance, used a hydrogel based on HA to deliver CRISPR/Cas9 to mice’s retinas while preventing retinal degeneration ( Yang et al, 2021 ). A system of hyaluronic acid-based nanoparticles was used in one study to deliver CRISPR/Cas9 to cancer cells.…”

Section: Need For Biomaterials: Advantages Over Other Delivery Methodsmentioning

confidence: 99%

Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy

Dubey,

Mostafavi

2023

Front. Chem.

View full text Add to dashboard Cite

The use of biomaterials in delivering CRISPR/Cas9 for gene therapy in infectious diseases holds tremendous potential. This innovative approach combines the advantages of CRISPR/Cas9 with the protective properties of biomaterials, enabling accurate and efficient gene editing while enhancing safety. Biomaterials play a vital role in shielding CRISPR/Cas9 components, such as lipid nanoparticles or viral vectors, from immunological processes and degradation, extending their effectiveness. By utilizing the flexibility of biomaterials, tailored systems can be designed to address specific genetic diseases, paving the way for personalized therapeutics. Furthermore, this delivery method offers promising avenues in combating viral illnesses by precisely modifying pathogen genomes, and reducing their pathogenicity. Biomaterials facilitate site-specific gene modifications, ensuring effective delivery to infected cells while minimizing off-target effects. However, challenges remain, including optimizing delivery efficiency, reducing off-target effects, ensuring long-term safety, and establishing scalable production techniques. Thorough research, pre-clinical investigations, and rigorous safety evaluations are imperative for successful translation from the laboratory to clinical applications. In this review, we discussed how CRISPR/Cas9 delivery using biomaterials revolutionizes gene therapy and infectious disease treatment, offering precise and safe editing capabilities with the potential to significantly improve human health and quality of life.

show abstract

Section: Need For Biomaterials: Advantages Over Other Delivery Methodsmentioning

confidence: 99%

Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy

Dubey,

Mostafavi

2023

Front. Chem.

View full text Add to dashboard Cite

show abstract

“…In the case of reduced bioavailability, the viability of therapeutic agents for AMD becomes hampered, as they require frequent administration [ 80 ]. The approaches under investigation have attempted to improve the bioavailability of the drugs either by using nanoparticulate carriers [ 81 ], sustained-release products [ 82 ], or penetration enhancers [ 83 ]. This section of the review is focused on a discussion of novel drug delivery systems targeting different routes of administration ( Figure 3 ), with a special emphasis on their applications and limitations.…”

Section: Novel Drug Delivery Systems For Amdmentioning

confidence: 99%

Novel Approaches in the Drug Development and Delivery Systems for Age-Related Macular Degeneration

Paliwal

Prajapati

Srichana

et al. 2023

Life

View full text Add to dashboard Cite

The number of patients with ocular disorders has increased due to contributing factors such as aging populations, environmental changes, smoking, genetic abnormalities, etc. Age-related macular degeneration (AMD) is one of the common ocular disorders which may advance to loss of vision in severe cases. The advanced form of AMD is classified into two types, dry (non-exudative) and wet (exudative) AMD. Although several therapeutic approaches are explored for the management of AMD, no approved therapy can substantially slow down the progression of dry AMD into the later stages. The focus of researchers in recent times has been engaged in developing targeted therapeutic products to halt the progression and maintain or improve vision in individuals diagnosed with AMD. The delivery of anti-VEGF agents using intravitreal therapy has found some success in managing AMD, and novel formulation approaches have been introduced in various studies to potentiate the efficacy. Some of the novel approaches, such as hydrogel, microspheres, polymeric nanoparticles, liposomes, implants, etc. have been discussed. Apart from this, subretinal, suprachoroidal, and port delivery systems have also been investigated for biologics and gene therapies. The unmet potential of approved therapeutic products has contributed to several patent applications in recent years. This review outlines the current treatment options, outcomes of recent research studies, and patent details around the novel drug delivery approach for the treatment of AMD.

show abstract

“…The transition to nAMD is characterized as progression to advanced dry AMD, and the presence of geographic atrophy is known as progression to AMDrelated exudation. Predictions of AMD development may enable prompt surveillance, early discovery, and treatment, improving visual results [26].…”

Section: Diagnosismentioning

confidence: 99%

Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment

Vyawahare¹,

Shinde²

2022

Cureus

View full text Add to dashboard Cite

The greatest global root of irremediable amaurosis in the venerable is age-related macular degeneration (AMD), a complex eye condition. Clinically, AMD is characterized as being in an early stage to late stage and initially affects the macula, which is the center of the retina (advanced AMD). Age-related cellular and metabolic imbalance are made worse by the creation of excessive amounts of free radical species, which causes mitochondrial malfunction. As a result, in AMD-affected eyes, the deprivation of melanocytes, confection, and eventually atrophy within the retinal tissue are caused by the continued proliferation of oxidative stress caused by systemic antioxidant capacity depletion.In the urbanized, industrialized world, age-related macular degeneration (AMD) is one of the major causes of central vision loss in the older age group. Although several causes and mechanisms for the dysfunction and degeneration of the retinal pigment epithelium (RPE) have previously been identified, the condition's symptoms are still not fully understood. Etiopathogenesis is still not entirely understood. As a result, the RPE fails, allowing an accumulation of aberrant misfolded proteins, due to the loss of anatomical control over oppression, altered homeostasis, dysfunctional lipid homeostasis, and failure of mitochondria.Due to the multitude of interconnected processes, numerous complicated therapy combinations will probably be the best option to deliver the best visual outcomes; these combinations will vary depending on the kind and degree of the condition being treated. Undoubtedly, this will lead to the development of customized preventative medications and, hopefully, the revelation of a potential cure. All the mechanisms involved in the etiology of AMD should be continuously probed to create covariates for other contemporaneous or future problems.

show abstract

Nanotechnology for Age-Related Macular Degeneration

Cited by 11 publications

References 122 publications

Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy

Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy

Novel Approaches in the Drug Development and Delivery Systems for Age-Related Macular Degeneration

Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment

Contact Info

Product

Resources

About